China's Leading Healthcare Market Player Posts First-Quarter Revenue Growth of 18%

Mr. KAM Yuen, Chairman of Golden Meditech, said that the Group, leveraging its continued market leadership of all its core business segments, aims to maintain strong growth momentum through new product launches and the expanding business scope of its Healthcare Services Segment.

Over the three months ended 30 June 2008, the Medical Devices Segment reported revenue of HK$67,764,000, accounting for 65% of the Group's total, while the Cord Blood Bank operations yielded a 47% increase of turnover to HK$ 36,866,000, accounting for 35% to the Group's total turnover.

Mr. KAM said the Group plans to launch two new SFDA-approved devices this year, namely the Plasma Exchange System and the Accelerated Thermostatic Infusion Pump. The two new products, complementing the segment's ABRS product, will contribute significantly to the growth of the Segment in the future.

The Cord Blood Bank operations inGuangdong Province, benefiting from application of the same successful sales and marketing models used inBeijing, witnessed robust revenue growth and it now contributed 39% to the Segment's total turnover in the quarter under review.

To meet the escalating demand, the Group will launch two new storage facilities this calendar year and this will greatly enhance the service quality and capacity in bothBeijing andGuangdong Province.

In the period under review, the Group has made a significant breakthrough in its bid to enter intoChina's hospital services market. The Group plans to acquire the Daopei Hospital Group at a total consideration of HK$830 million. The acquisitions will not only create huge synergies between the Group's core businesses and the target businesses, but also enhance the Group's business structure and presence inChina. In addition, with its strong earnings prospect, the management expects the hospital management business to become one of the key earnings drivers in the future.

Mr. KAM said that as a fast-growing healthcare corporation focused on the China market, Golden Meditech stands to benefit from the structural growth opportunities inChina's healthcare industries. The management is committed to achieve the Group's strategic goals and enhance shareholders' value and returns by successfully implementing corporate strategies. The management mobilized HK$14,336,000 for a share buyback program so far this financial year.

Golden Meditech: Founded in 2000 and listed on the Growth Enterprise Market of the Stock Exchange of Hong Kong Limited in December 2001, Golden Meditech is the first hi-tech medical device enterprise that went public outside of the PRC. During the past few years, thanks to its great efforts in innovation and market expansion, as well as its first-mover abilities in capturing the emerging market opportunities, Golden Meditech's medical devices, cord blood banking services and natural herbal medicines and have all established dominant positions in all business segments. Going forward, Golden Meditech will continue its pursuit of becomingChina's leading integrated medical group through organic growth, acquisition and strategic investment.

    For enquiries, please contact the investor relations department of Golden
Meditech Company Limited.

    Dennis Haikuan Lu
    Tel:     +852-3605-8138
    Fax:     +852-3605-8181
    Email:   ir@goldenmeditech.com
    Address: 48/F., Bank of China Building, 1 Garden Road, Central, Hong Kong

SOURCE Golden Meditech Company Limited

Copyright © 2009, PRNewswire
Copyright © 2009, NewsBlaze, Daily News

Tags: ,HEA,MTC,ASI,ERN,GM-Revenue-Growth